Top Story

Positive ongoing results in phase 1/2 trial in noninfectious uveitis

October 23, 2014

Seven out of eight patients with noninfectious uveitis receiving a suprachoroidal injection of triamcinolone acetonide achieved clinically meaningful reduction in retinal thickness at 8 weeks, according to a press release from Clearside Biomedical Inc.

Five of these seven patients experienced a reduction in retinal thickness to below 310 microns, which represents the maximum retinal thickness for approximately 95% of the population with normal retinas, according to the press release.

Brien Holden Vision Institute to launch commercial entities

October 21, 2014
The Brien Holden Vision Institute is in the process of bringing to market advanced products for myopia and myopia control, presbyopia, and the detection and management…
figure Meeting News Coverage

Clinical trials accumulate data for novel anti-VEGF

October 21, 2014
CHICAGO — A new anti-VEGF indicated for use in wet age-related macular degeneration achieved clinically meaningful and durable vision improvement in several…

Stem cell-derived RPE cells shown to be safe in patients with AMD

October 21, 2014
Advanced Cell Technology Inc. announced that phase 1/2 clinical data showed positive long-term safety when ACT’s retinal pigment epithelium cells were used for…
CME
figure

Postoperative Inflammation and Pain: Elimination of the Dynamic Duo to Improve Patient Outcomes

This activity is supported by an educational grant from Bausch + Lomb.

Cataract surgery has improved in both safety and outcomes in recent years. With advances in surgical techniques…
More »
Meeting Highlights Video
figure

Nanosecond YAG laser effectively treats vitreous floaters

October 11, 2014
LONDON – At the European Society of Cataract and Refractive Surgeons meeting here, Marie-Jose Tassignon
More »

Filter By:

Positive ongoing results in phase 1/2 trial in noninfectious uveitis

October 23, 2014
Seven out of eight patients with noninfectious uveitis receiving a suprachoroidal injection of triamcinolone acetonide achieved clinically meaningful…

Brien Holden Vision Institute to launch commercial entities

October 21, 2014
The Brien Holden Vision Institute is in the process of bringing to market advanced products for myopia and myopia control, presbyopia, and the…
figure Meeting News Coverage

Clinical trials accumulate data for novel anti-VEGF

October 21, 2014
CHICAGO — A new anti-VEGF indicated for use in wet age-related macular degeneration achieved clinically meaningful and durable vision…

Stem cell-derived RPE cells shown to be safe in patients with AMD

October 21, 2014
Advanced Cell Technology Inc. announced that phase 1/2 clinical data showed positive long-term safety when ACT’s retinal pigment epithelium…
figure Meeting News Coverage

LUMINOUS study interim results show VA preserved with ranibizumab

October 20, 2014
CHICAGO — One- and 2-year follow-up data indicate expected preservation of visual acuity with relatively few injections of ranibizumab in…
figure Meeting News Coverage

Aflibercept may minimize treatment burden in patients with CRVO

October 20, 2014
CHICAGO — The cystoid macular edema-free interval in patients with non-ischemic central retinal vein occlusion previously treated with…

Frontotemporal dementia may be detected through the eye

October 20, 2014
Diopsys announced in a press release that research scientists may have found a direct correlation with functional cell loss in the retina and signs…
figure Meeting News Coverage

Data suggest link between likelihood, onset of multiple sclerosis, uveitis

October 19, 2014
CHICAGO — Nearly 60% of patients with multiple sclerosis and uveitis were diagnosed with each disease within a 5-year period, according to…
Meeting News Coverage

iPhone ophthalmoscope may be effective, lower cost diabetic retinopathy tool

October 19, 2014
CHICAGO — An iPhone ophthalmoscope may be a cost-saving and effective tool used for the screening of diabetic retinopathy in underserved…
figure Meeting News Coverage

Response to AREDS formulation depends on genotype

October 18, 2014
CHICAGO – The response to AREDS supplementation in patients with age-related macular degeneration varies greatly based on CFH and ARMS2 risk…
More Headlines »